Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin + BeEAM for CD30+ Lymphomas
NCT03187210Phase 2Suspended
- Sponsor
- Insel Gruppe
- Start
- Sep 2018
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in CD30-positive lymphoma, sponsored by Insel Gruppe. Started Sep 2018; status: suspended.
02
Drugs
brentuximab vedotin
03
Conditions
CD30-positive lymphoma
Beyond the preview
Go deeper on NCT03187210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03187210.